{"name":"Pasithea Therapeutics","slug":"pasithea","ticker":"KTTA","exchange":"NASDAQ","domain":"pasithea.com","description":"Pasithea Therapeutics is a biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders. The company's pipeline includes several promising candidates for psychiatric and neurological conditions. With a strong focus on CNS therapeutics, Pasithea Therapeutics is well-positioned to capitalize on the growing demand for innovative treatments in this space.","hq":"Miami, FL","founded":0,"employees":"","ceo":"Tiago Reis Marques","sector":"CNS / Psychiatry","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$15M","metrics":{"revenue":3200000,"revenueGrowth":3130.4,"grossMargin":0,"rdSpend":7198494,"netIncome":-13904584,"cash":16064719,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"PTP203 patent cliff ($0.0B at risk)","drug":"PTP203","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-01","label":"PTP202 patent cliff ($0.0B at risk)","drug":"PTP202","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Pasithea Therapeutics Announces FDA Clearance for Phase 2 Clinical Trial of PTP203","summary":"Pasithea Therapeutics received FDA clearance to initiate a Phase 2 clinical trial of PTP203, a novel treatment for treatment-resistant depression.","drugName":"PTP203","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Pasithea Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Pasithea Therapeutics reported its third-quarter 2023 financial results, highlighting progress in its pipeline and operational efficiency.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-25","type":"deal","source":"simplywall.st","summary":"Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st","headline":"Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOR0JIQW04NlVUU1Nhb1M5VEtHd1hzVkdsOXQtdTBQR2xybjVUTDNoQ0ZqZWZva2IxRmJ3TmFjc3dJMzlkNU9DVVNTTWNVWVhsOUk5ck44VG9lWTBocExfUU8yb2w3amJpV1FubV9UV2dvSDJDY0trZGtFMW1OY1pKaWhZNTNHcFlfSXpVYmRaZFRveGRGRU44RTh4SjVMZGhhRzNBUzdYbDNPN1hmT2l3MEY3S0dOU09Jbnc?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"NF1-PN drug developer Pasithea to present at Oppenheimer event - Stock Titan","headline":"NF1-PN drug developer Pasithea to present at Oppenheimer event","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOZERTTmZBWmpnQklMTHo1ZGFVNzJwQnU3WXF0cy1fWEJ4SHJOVnZlQ2tzYTRYLTlOYmFySzlnQVA5a1h0aFZKNTNVTHM5SHJiZWdrVVhsTFl5YkJ5ZWhNQmIwUHY2ZE1NZmtmMjBuXzVFeS0wSE4tTFpqWlBFWlJ4bFY3UDRLWExRbFBEM0pGMmQ5Wm5mSTZMUmptbTZ2QXdlckpLNVhHOGtKZWsyenJUc2hlTE9RVjM2clpjQnhHQjJOeXFo?oc=5","date":"2025-11-28","type":"pipeline","source":"Stocktwits","summary":"Why Did KTTA Stock Soar A Whopping 43% Today? - Stocktwits","headline":"Why Did KTTA Stock Soar A Whopping 43% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOcEdnbUNseVotaFpEN2NEUHdfaHJheU5qYU96TTBLUjJsT1FCb0VGd05acVF0aVNlTEN5SDEzeXAyc25pX0x3bkh0MjVxeTNqbmUtSlk0QTgtMTlHLUJTclltLWZaTFlBTVdLeUw3VGppczVCeTF3VkhmTklSR3h6VEhwanNuVEsxRlZTaFVPMUc4QlNSSXJHV0JNWjFIMjhvNzJJcUhGRGtqZWV0bGxDVDNPQUhQQQ?oc=5","date":"2025-11-28","type":"pipeline","source":"Stock Titan","summary":"Pasithea Therapeutics (Nasdaq: KTTA) prices 80M shares at $0.75, extending cash runway through 1H 2028 - Stock Titan","headline":"Pasithea Therapeutics (Nasdaq: KTTA) prices 80M shares at $0.75, extending cash runway through 1H 2028","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5EdnUzeXF6N3dvYmM5UHhZR3psNzFHcEh1dDJfNlFRVUxUdGpQbGFjOXZWS3VLN0MwQURzaE1MZjl5MVZONzFoT3BGaXplNWg5UTZz?oc=5","date":"2025-05-06","type":"pipeline","source":"Stock Titan","summary":"KTTA Stock Price, News & Analysis | Pasithea Therapeutics - Stock Titan","headline":"KTTA Stock Price, News & Analysis | Pasithea Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1CUzNHcTRRRVhqS0hNSkpscGsxN2k4b0x1UHNtM2tRaGFBbUFRZ0N2QW5Uc3hJLVNBaHVOTkx4ek9pclVEUVRXajBDNFJkUjZE?oc=5","date":"2024-02-12","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5BNFIwNUJTeGdTVU16MnM1WTJENzVtNDdkTTVwaGNXQlRMbkxPNnRlX2xSa2tXR2huTk1JVDl5a2lVcU1CZ2NheWVwdHlkeUNpYUhZVmZxazJYRmhwZzNZ?oc=5","date":"2022-02-18","type":"pipeline","source":"ChartMill","summary":"KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill","headline":"KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBtTU9MMXNrdDJNcmE5R0JxMnZNY1N6d2lMd3ozU1U5bjhpckhhcTh0U2NSZUI3RmtkZzJOejBmUzhWRTJFalo4ZlJJeE1sWmEta2c?oc=5","date":"2021-11-10","type":"pipeline","source":"Yahoo Finance UK","summary":"Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK","headline":"Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPMkFTQ0pTSFVfeU1fUU9hdTlJLXM1MHhZWW16QmItQUNodnh3aXBxMzZxTlphRFE2R2RKYUN0c24zZkpXd214SjgtZF9QbE94UjhCQkY0SnVsZEY3Z0pNVmFVa3JyaGhUcEhScWNhZnVSVXN2aVZCbERVUldXNkloLUswbU1oa2t2?oc=5","date":"2021-10-14","type":"pipeline","source":"drugdiscoverytrends.com","summary":"What the ketamine boom could mean for pharma - drugdiscoverytrends.com","headline":"What the ketamine boom could mean for pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9ucnN2dWswZnQwd0RUZ25nRlVFNlRBUHplb0NtR2lqSWc0WTdER2Jya2Y1UjJPOFdqSldwbU5sMDdISm9hdE5YRjBzN2FGRDJ4UU1Xb2d1QVVfbWFr?oc=5","date":"2021-08-11","type":"pipeline","source":"TradingView","summary":"KTTA Stock Price and Chart — NASDAQ:KTTA - TradingView","headline":"KTTA Stock Price and Chart — NASDAQ:KTTA","sentiment":"neutral"}],"patents":[{"drugName":"PTP203","drugSlug":"ptp203","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"PTP202","drugSlug":"ptp202","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Neurocrine Biosciences","Vanda Pharmaceuticals","Pfizer"],"therapeuticFocus":["Central Nervous System (CNS) Disorders","Psychiatry"],"financials":{"source":"sec_edgar+yahoo","revenue":486559,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":486559,"period":"2022-12-31"},{"value":15062,"period":"2021-12-31"},{"value":15062,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7198494,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-13904584,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":16064719,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}